HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $38 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.0%

Neg 0% Neu 90% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $38 price target.